{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:10:53Z","timestamp":1774948253666,"version":"3.50.1"},"reference-count":10,"publisher":"American Association for Cancer Research (AACR)","issue":"3","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Summary:<\/jats:title>\n                  <jats:p>Aoki and colleagues have utilized single-cell RNA sequencing and imaging mass cytometry to describe the landscape of reactive, nonmalignant immune-cell populations present in classic Hodgkin lymphoma (cHL), and delineate their spatial proximity to malignant Hodgkin\u2013Reed\u2013Sternberg cells. From this study, they have identified a LAG3-expressing Tr1-type Treg cell population as prevalent mainly in MHC-II\u2013negative cHL, implying a potential functional relationship underlying the differential responsiveness of MHC-II\u2013negative versus MHC-II\u2013positive cHLs to immunotherapy.<\/jats:p>\n                  <jats:p>See related article by Aoki et al., p. 406.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1158\/2159-8290.cd-19-1538","type":"journal-article","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T13:25:34Z","timestamp":1583241934000},"page":"342-344","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Unraveling the Architecture of Classic Hodgkin Lymphoma One Cell at a Time"],"prefix":"10.1158","volume":"10","author":[{"given":"Daniel A.C.","family":"Fisher","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen T.","family":"Oh","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2020,3,3]]},"reference":[{"key":"2022060622151100200_bib1","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1634\/theoncologist.2018-0538","article-title":"Outcomes and toxicities of programmed death-1 (PD-1) inhibitors in Hodgkin lymphoma patients in the United States: a real-world, multicenter retrospective analysis","volume":"24","author":"Bair","year":"2019","journal-title":"Oncologist"},{"key":"2022060622151100200_bib2","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022060622151100200_bib3","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"key":"2022060622151100200_bib4","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"2022060622151100200_bib5","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J Clin Oncol"},{"key":"2022060622151100200_bib6","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-19-0680","article-title":"Single-cell transcriptome analysis reveals disease-defining T-cell subsets in the tumor microenvironment of classic Hodgkin lymphoma","volume":"10","author":"Aoki","year":"2020","journal-title":"Cancer Discov"},{"key":"2022060622151100200_bib7","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/bjh.12980","article-title":"Epstein-Barr virus infection induces an increase of T regulatory type 1 cells in Hodgkin lymphoma patients","volume":"166","author":"Morales","year":"2014","journal-title":"Br J Haematol"},{"key":"2022060622151100200_bib8","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood-2006-04-015164","article-title":"Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients","volume":"108","author":"Gandhi","year":"2006","journal-title":"Blood"},{"key":"2022060622151100200_bib9","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nmeth.2869","article-title":"Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry","volume":"11","author":"Giesen","year":"2014","journal-title":"Nat Methods"},{"key":"2022060622151100200_bib10","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic Hodgkin's lymphoma","volume":"362","author":"Steidl","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/10\/3\/342\/1813250\/342.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/10\/3\/342\/1813250\/342.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T22:15:21Z","timestamp":1654553721000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/10\/3\/342\/2386\/Unraveling-the-Architecture-of-Classic-Hodgkin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,1]]},"references-count":10,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3,3]]},"published-print":{"date-parts":[[2020,3,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-19-1538","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,1]]}}}